Testosterone and the prostate. The actual evidence.
The fear that testosterone causes prostate cancer persisted for 70 years based on a 1941 case series of 11 patients. The saturation model has replaced it. The modern evidence is reassuring. The monitoring protocol that follows from it is straightforward.
I. The historical fear and its origin.
The testosterone-prostate cancer hypothesis originated with Charles Huggins' 1941 work showing that castration regressed advanced prostate cancer. The inference followed: if low testosterone shrinks prostate cancer, high testosterone must grow it. Huggins received a Nobel Prize for this observation. The clinical inference attached to it lasted 70 years with limited direct supporting evidence.
The saturation model reframed this entirely. Morgentaler and Traish established that the prostate androgen receptor saturates at relatively low testosterone concentrations, approximately 200 to 250 ng/dL total testosterone. Above that saturation threshold, additional testosterone does not stimulate further prostate growth. The testosterone-to-prostate-growth relationship is not linear. verified [I]
II. TRT and prostate cancer risk: the modern data.
Multiple meta-analyses have not demonstrated increased prostate cancer incidence with testosterone replacement therapy in appropriately selected patients. Cui et al. pooled data across controlled TRT trials and found no significant increase in prostate cancer incidence or recurrence. verified [II]
The TRAVERSE trial (Lincoff 2023) added the highest-quality prospective data to this record. Secondary endpoint analysis showed no significant increase in prostate cancer diagnosis with testosterone versus placebo over 33 months of follow-up in a large, well-characterized cardiovascular risk population. verified [III]
The Belief-Surviving-Evidence Problem
The persistence of testosterone-prostate cancer fear in clinical medicine, three meta-analyses and a large randomized controlled trial after the saturation model's publication, represents one of medicine's clearest examples of belief surviving evidence. Clinicians who still reflexively avoid TRT in all men with prior prostate cancer, prior PSA elevation, or family history have not updated their priors on the available data. This is a clinical decision that should be made with current evidence and urological consultation. Not with 1941 assumptions.
III. PSA monitoring protocol.
Baseline. PSA before TRT initiation in all men age 40 and older. Men with family history of prostate cancer or African American men: consider baseline at 35.
Early follow-up. PSA at 3 to 6 months after TRT initiation. TRT can increase PSA by 0.5 to 1.0 ng/mL from baseline through the saturation mechanism. This is expected and does not indicate malignancy. verified [IV]
Velocity. PSA velocity, the rate of change, matters more than any single absolute value. PSA rise above 0.75 ng/mL per year warrants urological evaluation regardless of the absolute reading.
Absolute thresholds for urological referral: PSA above 4.0 ng/mL at any time. PSA above 3.0 ng/mL in men under 60. PSA velocity above 0.75 ng/mL per year.
IV. Prostate-specific considerations at TRT initiation.
Prior treated prostate cancer. TRT is increasingly used in appropriately selected men with low-risk prostate cancer who have had definitive treatment and are in sustained remission. This requires urological consultation and shared decision-making. It is not a blanket contraindication in 2024.
BPH (benign prostatic hyperplasia). TRT does not worsen urinary symptoms in men with well-controlled BPH. In men with severe, uncontrolled BPH symptoms, address the BPH first.
High baseline PSA. Evaluate and work up before initiating TRT. Do not start TRT with an unexplained PSA elevation on the table.
5-alpha reductase inhibitors. Finasteride and dutasteride reduce prostate DHT and suppress PSA by approximately 50%. Men on these medications will have artifactually low PSA readings. Use 2x the measured PSA as the effective PSA for risk stratification.
V. Prostate health optimization.
DHT (dihydrotestosterone) is the primary androgenic stimulus to the prostate. Testosterone converts to DHT via 5-alpha reductase in prostatic tissue. This is the mechanism targeted by finasteride and dutasteride.
Saw palmetto produces modest 5-alpha reductase inhibition. Evidence for BPH symptom relief is mixed across controlled trials. It is not an appropriate prostate cancer prevention measure.
Lycopene is an antioxidant carotenoid concentrated in tomatoes. There is an epidemiological association with reduced prostate cancer risk. The mechanism is plausible: antioxidant protection of prostatic DNA. It is not a substitute for PSA monitoring.
The Supplement Substitution Problem
The clinician who recommends saw palmetto or lycopene as prostate cancer prevention to a patient on TRT has moved from evidence-based medicine to supplement marketing. Neither compound has demonstrated prostate cancer prevention in controlled trials. PSA monitoring is the evidence-based intervention. Annual urological assessment is the infrastructure. Supplements are adjuncts at best, and weak ones. Do not let them displace the actual protocol.
VI. Annual prostate monitoring standard.
Year 1 on TRT: PSA at baseline, 3 months, 6 months, 12 months. Calculate velocity at each interval.
Year 2 and beyond: PSA annually. Digital rectal exam annually for men over 50 or with elevated risk.
Free-to-total PSA ratio is useful when total PSA is in the 4 to 10 ng/mL gray zone. Free PSA below 10% of total increases cancer probability. Above 25% reduces it.
MRI prostate. Multi-parametric MRI is increasingly first-line for prostate cancer evaluation in appropriately indicated patients, before biopsy. PI-RADS scoring guides biopsy decisions. inferred from current urology guidelines
The monitoring protocol answers one question at each time point: is the PSA moving in a pattern consistent with TRT physiology, or is it moving in a pattern that requires urological evaluation? The protocol exists to distinguish those two patterns early. verified [IV]
References
- Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and limits of androgen-dependent growth. Eur Urol. 2009. Saturation model: androgen receptor saturation at 200 to 250 ng/dL, non-linear testosterone-prostate growth relationship. verified
- Cui Y et al. The effect of testosterone replacement therapy on prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2014. No significant increase in prostate cancer incidence or recurrence across pooled TRT trials. verified
- Lincoff AM et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023. TRAVERSE trial secondary endpoint: no significant increase in prostate cancer diagnosis with testosterone versus placebo over 33 months. verified
- Bhasin S et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018. PSA monitoring recommendations: baseline, 3 to 6 months, annually thereafter; velocity and absolute threshold guidance. verified
- Thompson IM et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Engl J Med. 2004. PSA threshold context: absolute PSA alone is an incomplete risk stratifier. verified
THE PIVOTAL PROTOCOL is an intelligence and education layer, not a prescriber. The mechanisms and monitoring parameters described here are derived from the cited literature and from Pivotal's protocol design history. Every clinical decision belongs to a licensed physician with full knowledge of the case. Begin a conversation. Do not begin self-administration from a website.